Search

1 to 10 of 288
Sort by

Library Entry
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a short report on the final planned analysis of OPTiM, a randomized open-label phase III trial of T-vec in patients with unresectable stage IIIB–IVM1c melanoma. Authors: Robert H. I. Andtbacka , Frances Collichio , Kevin J....


Library Entry
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article reporting the results of a phase I study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of weekly ONC201. Authors: Mark N. Stein , Jyoti Malhotra , Rohinton S. Tarapore , Usha...


Library Entry
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article concluding that ICIs produce a spectrum of distinct classes of neurologic AEs that can cause significant morbidity and mortality and tend to occur early and with class-specific associations. Authors: Douglas B....


Library Entry
The promise of Immuno-oncology: implications for defining the value of cancer treatment

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a position article and guidelines. This paper defines ways in which treatment with I-O is different from other therapies. It also proposes key aspects and attributes of I-O therapies that should be considered in any assessment of...


Library Entry
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a short report discussing a phase II clinical trial investigating the feasibility of intermittent nivolumab dosing in RCC. JITC (2019) 7 :127 Authors: Moshe C. Ornstein , Laura S. Wood , Brian P. Hobbs , Kimberly D. Allman ...



Library Entry
Advances in Cancer Immunotherapy™ Webinar Series: Updates from the Field - Clinical Updates from SITC 2018 (Presentation Slides)

This webinar provided an update on developments in the field relating to content presented at the Advances in Cancer Immunotherapy programs and focused on applicable information for a clinical audience. More specifically, program organizers Christian M. Capitini, MD, and Zachary S. Morris,...

Advances in Cancer Immunotherapy Updates from the Field - Clinical Updates from SITC 2018.pdf




Library Entry
Webinar: Stage III Non-small Cell Lung Cancer and Immunotherapy

LUNGevity sat down with Patrick Forde, MD (MB, BCH), Associate Professor of Oncology at the Johns Hopkins School of Medicine, to discuss the results of the PACIFIC trial and what it means for the lung cancer survivor community. Dr. Forde is an expert on immunotherapies for lung cancer and has...